Immunotherapy drugs that are currently utilized in breast cancer comprise of Checkpoint Inhibitors (ICI), namely PD-1 and PDL-1 inhibitors and HER2-directed monoclonal antibodies [7]. This evidence concerns the gene ERBB2 and breast cancer.